Status:
UNKNOWN
An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type
Eligibility:
All Genders
18+ years
Brief Summary
To retrospectively collect information on DLBCL patients treated with orelabrutinib in combination with standard first-line regimens, pooled analysis of the association between recent efficacy and pat...
Eligibility Criteria
Inclusion
- Age ≥ 18 years Diffuse large B-cell lymphoma (DLBCL) diagnosed by histopathology of the tumour, without any previous anti-tumour therapy or after ≤2 cycles of R-CHOP(like) or Pola-R-CHP therapy only
- Have a clear efficacy evaluation
- Patients eligible for Non-GCB or extra-nodal or dual expression or who, in the judgement of the investigator, would benefit from treatment with Orelabrutinib following genetic testing.
- Patients treated with at least 2 cycles of orelabrutinib in combination with an R-CHOP(like) or Pola-R-CHP regimen
Exclusion
- Lymphoma involving the central nervous system or soft meningeal metastases
- Transforming lymphoma, i.e. from other types of lymphoma such as follicular lymphoma, marginal zone lymphoma or chronic lymphocytic leukaemia or small B-cell lymphoma
- Primary mediastinal large B-cell lymphoma
- Patients with poorly controlled cardiovascular disease, infectious disease, etc.
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 30 2025
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT06015464
Start Date
September 1 2023
End Date
July 30 2025
Last Update
August 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematological Department, People's Hospital of Jiangsu Province
Nanjing, Jiangsu, China, 210029